New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
2 nd Annual Essentials in Primary Care<br />
Fall Conference<br />
Friday, November 11, <strong>2011</strong><br />
Dabigatran - Pradaxa<br />
• A direct thrombin<br />
inhibitor indicated to<br />
reduce the risk of stroke<br />
and systemic embolism<br />
in patients with nonvalvular<br />
atrial fibrillation<br />
• 75 mg and 150 mg<br />
capsules BID $253.00/60<br />
• No need to monitor INR<br />
• Not reversible with<br />
vitamin K or FFP<br />
(consider factor<br />
concentrates or dialysis)<br />
Dabigatran- Pradaxa<br />
RE-LY (Randomized Evaluation of Long-term Anticoagulant Therapy),<br />
a randomized trial comparing two blinded doses of dabigatran (110<br />
mg twice daily and 150 mg twice daily) with open-label warfarin<br />
(dosed to target INR of 2 to 3) in 18,113 patients with non-valvular,<br />
persistent, paroxysmal, or permanent atrial fibrillation and one or<br />
more of the following additional risk factors:<br />
• Previous stroke, transient ischemic attack (TIA), or systemic<br />
embolism<br />
• Left ventricular ejection fraction
Change language